“This exclusive agreement with VW is a significant opportunity to help even more veterans and other members of the general public who struggle daily with anxiety, depression and PTSD,” said Steven Inglefield, director of the operating offer of Ketamine One.
KetamineOne Capital has announced that it has entered into a one-year agreement with Victoria Wellness Mental Health Residential and Addiction Treatment Center (VW) to be its exclusive ketamine treatment provider.
The Vancouver, B.C.-based company said it and the center have launched a first-class, best-practice, ketamine integrated therapy experience (KITE) program lasting six weeks.
The first three weeks of the KITE program are structured to provide clients with a unique opportunity to benefit from fast-acting, evidence-based, medically supervised ketamine administration to help address long-standing and resistant mental health issues. to prescriptions such as depression and post-traumatic stress disorder (PTSD), the company added.
READ: KetamineOne Capital says its common stock has been successfully transferred to the OTCQB
“This exclusive agreement with VW is a significant opportunity to help even more veterans and other members of the general public who struggle daily with anxiety, depression and PTSD,” said Steven Inglefield, director of the offer to operate Ketamine One (NEO: MEDI.AQN). A declaration.
“Growing our network of clinics, both directly and indirectly, such as through this agreement, is central to the company’s competitive strategy. We are working hard to expand our operations and ultimately that means working hard to help more people,” he added.
Ketamine One (NEO: MEDI.AQN) noted that VW, based in Gores Landing, Ontario, is a residential rehabilitation facility and mental clinic focused on treating anxiety, depression and PTSD by offering personalized therapeutic treatment programs with a connection to nature to veterans and the general public. By integrating ketamine-assisted psychotherapy into its service offering, it aims to become a leader in the mental health industry.
As part of the program, Ketamine One (NEO:MEDI.AQN) said ketamine doses will be supplemented with specialized and integrated ketamine-assisted psychotherapy. The KITE program will also allow VW customers to embark on a comprehensive, premium six-week residential recovery experience, featuring the best in data-driven recovery therapies and holistic healing traditions.
Based on the previously announced Ketamine One partnership, customers will be triaged and psychologically assessed by iHealthOX. Those deemed suitable for treatment will receive ketamine intravenously at an off-site third-party pain center.
“This partnership allows us to provide residential care with ketamine to veterans, military personnel and first responders who suffer from PTSD, depression and other mental health issues,” said VW Executive Director Joe Ann Kortman. “In my personal experience, you can get better and our KITE program is designed to help you fly.”
Additionally, Ketamine One reported that data collection from the first participants in its previously announced single-arm, open-label study of PTSD patients undergoing the proprietary physiotherapy program at its IRP Health clinics began on January 4, 2022. .
The company also announced that the rebranding of IRP Health is now complete. Those interested can visit www.irphealth.ca to experience the new brand, he says.
KetamineOne Capital is focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It strives to provide the essential infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry.
KGK Science Inc. is the Company’s 100% owned contract research division, placing it at the forefront of high-end clinical research based on the subsidiary’s history and extensive experience in the pharmaceuticals, cannabis and the emerging industries of psychedelic medicine.
Contact the author at [email protected]